Overview

Gender

male

Bill became FLX Bio’s Chief Medical Officer in 2015, bringing with him extensive experience both in clinical immunotherapy and in the translational and clinical development of novel therapeutics to treat cancer. He joined FLX Bio after serving as the Vice President of Clinical Development at Igenica Biotherapeutics where he led the clinical development of antibody-based therapeutics. Prior to Igenica, Bill served as a Senior Medical Director in the Exploratory Clinical Development (BioOncology) group at Genentech, where for seven years he led the development of multiple small molecule, antibody, and antibody-drug conjugate programs from IND filing to Phase III, including clinical development of Gazyva® (obinutuzumab) and Venclexta™ (venetoclax).

Bill received his A.B. in Molecular Biology from Princeton University and both his M.D. and his Ph.D. in Microbiology and Immunology from the Stanford University School of Medicine, where he studied cellular immunology in the laboratory of Mark Davis, Ph.D. Bill completed his internship and residency in Internal Medicine at the University of California, San Francisco, and received his training in Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy methods to treat leukemia.